Replies to post #161588 on NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

I hope you are right. Of all the variable possibilities on how this plays out my personal favourite is to unblind PFS and leave OS blinded (I have read this posted several times on this board by a number of posters) I am sure PFS data must be adequately ripe by now and has been modelled (Bohsie et al) demonstrating a successful outcome, it can also be argued it was also endorsed by NWBO (by virtue of the fact they referenced this modelling in their filing). Linda's ASM statements aside I do feel the spring refresh should coincide with data lock leading to top line PFS (minimum) being announced at ASCO, going further beyond ASCO raises serious questions IMO GLTA